• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Interviews with patients and their spouses to capture personal descriptions of early treatment experience with mogamulizumab for mycosis fungoides (MF) and Sezary syndrome (SS)

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Gibson, J.
    Beeler, D.
    Rynkiewich, K.
    Spiegelhalter, K.
    Williams, A.
    Affiliation
    The Christie NHS Foundation Trust, Manchester, United Kingdom
    Issue Date
    2021
    
    Metadata
    Show full item record
    Abstract
    Background: Mycosis fungoides (MF) and Sézary syndrome (SS) are rare and chronic non-Hodgkin lymphomas that present in skin and can progress to involve extracutaneous sites. For many patients, skin lesions are disfiguring with an intractable itch. Other symptoms can include difficulty regulating body temperature and sleep disturbance. Symptomatic MF and SS can have a negative impact on health-related quality of life (HRQL). Mogamulizumab is approved in Europe for the treatment of adult patients with MF or SS after at least one prior systemic therapy based on the efficacy and safety demonstrated in the phase 3 MAVORIC trial (NCT01728805). Objectives: To capture personal descriptions from patients and their spouses of the burden of MF and SS before starting mogamulizumab treatment and their early treatment experience. Methods: Five patients and three spouses were recruited at two hospital clinics in the UK. Following informed consent, 1:1 semi-structured, 60-minute telephone interviews were conducted. Participants were asked about their experience of symptoms and impact of their condition on domains of HRQL prior to starting treatment with mogamulizumab, and any changes during the first six months of treatment. Spouses were also asked about any impact on their role as a carer since mogamulizumab treatment was initiated. Interviews were transcribed, responses coded, and narrative summary provided. Findings: Prior to treatment with mogamulizumab, patients and their spouses reported moderate-to-severe problems with all skin-related symptoms and regulating their body temperature. The majority described fatigue and sleep problems, with spouses also reporting patients’ moderate-to-severe problems with those symptoms. On starting mogamulizumab, both patients and their spouses described rapid improvement in itching, with gradual improvement in skin flaking, redness, and pain/discomfort. Similarly, body temperature regulation, fatigue and sleep quality gradually improved in the first six months of treatment. There was a wide distribution in the reported level of disease impact on HRQL domains prior to treatment with mogamulizumab including emotional well-being, ability to self-care, activities of daily living, social well-being, and family relationships. Symptom presentation on hands and feet was associated with greater impact on these QoL domains. For those with moderate-to-severe problems pre-treatment, patients and spouses described a meaningful reduction in the level of impairment, sometimes within the first few months of treatment. Spouses reported that their everyday life as a carer had positively changed since their partner had received treatment with mogamulizumab. Conclusion: Participants described multiple symptoms and the detrimental impact on their HRQL prior to treatment with mogamulizumab. There was a rapid improvement in itching with improvement in other symptoms and overall HRQL in the first six months of mogamulizumab treatment.
    Citation
    Gibson J, Beeler D, Rynkiewich K, Spiegelhalter K, Williams A. Interviews with patients and their spouses to capture personal descriptions of early treatment experience with mogamulizumab for mycosis fungoides (MF) and Sézary syndrome (SS) Vol. 156, European Journal of Cancer. Elsevier BV; 2021. p. S64.
    Journal
    European Journal of Cancer
    URI
    http://hdl.handle.net/10541/624876
    DOI
    10.1016/S0959-8049(21)00746-2
    Additional Links
    https://dx.doi.org/10.1016/S0959-8049(21)00746-2
    Type
    Meetings and Proceedings
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/S0959-8049(21)00746-2
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.